Statistical Analysis In Human Abuse Potential Studies

Determining the abuse potential of centrally acting drugs is a high-stakes endeavor for public health and regulatory approval. To move beyond guesswork, researchers utilize Human Abuse Potential (HAP) studies—randomized, double-blind crossover trials that transform subjective human experiences into rigorous data. These studies rely on specific benchmarks, such as E_max (peak effect), to compare a test drug against both placebos and known positive controls.

The statistical validity of these trials rests on two pillars: study sensitivity, which confirms the positive control produces the expected "liking" response, and inferential testing, which measures the test drug’s relative risk. By applying precise margins to visual analog scales, statisticians can objectively determine if a drug’s effects warrant strict scheduling or specific warning labels. Navigating these nuanced analyses ensures that regulatory decisions are rooted in evidence, providing a clear map of a drug’s safety profile before it reaches the public.